Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival

Human Pathology

Volumn 31, Issue 4, 2000, Pages 475-481

  Grogan, Thomas M ^a,b,c,d   Fenoglio Prieser, Cecilia ^a,b,d   Zeheb, Ronald ^a,b,d   Bellamy, William ^a,b,d   Frutiger, Yvette ^a,b,d   Vela, Elizabeth ^a,b,d   Stemmerman, Gerald ^a,b,d   Macdonald, James ^a,b,d   Richter, Lynne ^a,b,d   Gallegos, Alfred ^a,b,d   Powis, Garth ^a,b,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Gastric carcinoma; Thioredoxin oncogene

Indexed keywords

THIOREDOXIN;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CORRELATION FUNCTION; DNA DAMAGE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; STOMACH CARCINOMA;

EID: 0034065729     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hp.2000.6546     Document Type: Article

References (26)

1. Holmgren A. Thioredoxin and glutaredoxin systems J Biol Chem 264 1989 13963 13966
2. Luthman M. Holmgren A. Rat liver thioredoxin and thioredoxin reductase: Purification and characterization Biochemistry 21 1982 6628 6633
3. Gasdaska P.Y. Oblong J.E. Cotgreave I.A. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF):Thioredoxin mRNA is elevated in some human tumors Biochim Biophys Acta 1218 1994 292 296
4. Laurent T.C. Moore E.C. Reichard P. Enzymatic synthesis of deoxyribonucleotides VI: Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B J Biol Chem 239 1964 3436 3444
5. Matthews J.r. Wakasugi N. Virelizier J.-L. Thioredoxin regulates the DNA binding activity of NF-kappaB by reduction of a disulphide bond involving cysteine 62 Nucl Acids Res 20 1992 3821 3830
6. Cromlish J.A. Roeder R.G. Human transcription factor IJIC (TFRIC): Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding J Biol Chem 264 1989 18100 18109
7. Bannister A.J. Cook A. Kouzarides T. In vitro DNA binding activity of Fos/Jun and BZLFI but not C/EBP is affected by redox changes Oncogene 6 1991 1243 1250
8. Grippo J.F. Tienrungroj W. Dahmer M.K. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin J Biol Chem 258 1983 13658 13664
9. Wakasugi N. Tagaya Y. Wakasugi A. Adult T-cell leukemiaderived facto r/Thioredoxin produced by both human T-lymphotropic virus type and Epstein-Barr virus-transformed lymphocytes,acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2 Proc Natl Acad Sci U S A 87 1990 8282 8286
10. Yodoi J. Tursz T. ADF, a growth-promoting factor clerived from adult T cell leukemia and homologous to thioredoxin: Involvement in lymphocyte immo tion by HTLV 1 andEBV Acv Cancer Res 57 1991 381 411
11. Powis G. Oblong J.E. Gasdaska P.Y. The thiorecloxin/thioredoxin recluctase redox system and control of cell growth Oncol Res 6 1994 539 544
12. Oblong J.E. Berggren M. Gasdaska P.Y. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thiorecloxin reductase and elimination of mitogenic properties of thiorecloxin J Biol Chem 269 1994 11714 11720
13. Gasdaska J.r. Berggren M. Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism Cell Growth Differ 6 1995 1643 1650
14. Kitaoka Y. Sorachi K. Nakamura H. Detection of adult T-cell leukemia-clerived factor/human thioredoxin in human serum Immunol Lett 41 1994 155 161
15. Rubartelli A. Bajetto A. Allavena G. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway J Biol Chem 267 1992 24161 24164
16. Gallegos A. Gasdaska J.R. Goodman D. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype ofbreast cancer cells Cancer Res 56 1996 5765 5770
17. Baker A. Briehl M. Payne C. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo Cancer Res 57 1997 5162 5167
18. McDonnell T.J. Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14: 18) Nature 349 1991 254 256
19. Berggren M. Gallegos A. Gasdaska J.R. Thioredoxin and thiorecloxin recluctase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia Anticancer Res 16 1996 3459 3466
20. Grogan T.M. Casey T.T. Miller T.P. Automation of immunohistochemistry Weinstein R.S. Advances in Pathology and Laboratory Medicine vol 6 1993 Mosby St Louis, MO 253 283
21. Grogan T.M. Rangel C. Rimsza L. Kinetic-mode, automated double-labeled immunohistochemistry and in situ hybridization in diagnostic pathology Adv Pathol Lab Med 8 1995 79 100
22. Miller T. Grogan T. Dahlberg S. Prognostic significance of the Ki67 associated proliferation antigen in aggressive nonHodgkin's lymphomas: A prospective Southwest Oncology GroupTrial Blood 83 1994 1460 1466
23. Gavrieli Y. Sherman Y. Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J Cell Biol 119 1992 493 501
24. Grasl-Kraupp B. Ruttkay-Nedecky B. Koudelka H. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note Hepatology 21 1995 1465 1468
25. Fujii S. Nanbu Y. Nonogald H. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamousepithelium Cancer 68 1991 1583 1591
26. Kawahara N. Tanaka T. Yokomiro A. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin Cancer Res 56 1996 5330 5333